Key points from article :
The next big wave in biotech investments will focus on longevity drugs—medicines aimed at extending human lifespan. This emerging field is expected to develop in three distinct phases over the next decade. The first phase, which is already in progress, involves pharmaceutical giants like Eli Lilly and Biogen creating treatments for age-related diseases such as Alzheimer’s. While these drugs aren't explicitly marketed as "longevity" treatments, they effectively contribute to longer, healthier lives by addressing common ageing-related conditions.
The second phase is anticipated to bring a wave of activity from smaller biotech companies, many of which will make ambitious claims about new drugs that could potentially slow the ageing process. However, this phase will be fraught with risks for investors, as many of these companies may not live up to their promises. Some may succeed in developing treatments that offer modest extensions to lifespan, but overall, the phase will likely be marked by both breakthroughs and failures.
By the early 2030s, the third phase is expected to see more advanced and mainstream longevity treatments, as the underlying science matures. At this stage, the market for these drugs will have expanded significantly, with the potential to extend both lifespan and health span beyond natural limits. Investors are advised to approach this evolving sector with caution, particularly in the earlier phases, where the risks are higher. The safest opportunities may arise as the industry matures and the most successful companies become clear.
